Peptide-Based ROR1-Targeting PET Ligands for Melanoma Tumor Imaging: Design and Preclinical Evaluation
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.6c00570 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Donglan Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, P.R. China. Hauptthemen laut MEDLINE: Receptor Tyrosine Kinase-like Orphan Receptors, Melanoma, Positron-Emission Tomography, Peptides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is overexpressed in multiple cancers while remaining largely absent in adult tissues, which makes it an attractive target for both tumor diagnosis and therapy. To enable noninvasive imaging of ROR1, four peptide-based PET ligands [68Ga]1–4 were rationally designed and evaluated for melanoma imaging. In vitro assays confirmed reasonable ROR1 binding affinity (KD = 481.0 and 44.9 nM, respectively) and specific cellular uptake of [68Ga]2 and [68Ga]3, which are functionalized with serum albumin-binding groups. Notably, microPET/CT imaging and biodistribution studies in B16F10, A375, and SK-MEL-28 tumor-bearing mice demonstrated that [68Ga]2 achieved the most favorable imaging performance, characterized by high tumor accumulation (up to 9.18% ID/g), sustained retention, and a relatively lower nonspecific background signal. These findings highlight [68Ga]2 as a promising candidate for ROR1-targeting PET imaging and underscore the potential of peptide-based ROR1 PET probes for tumor imaging and therapy guidance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, P.R. China.
- Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China.
- Hubei Key Laboratory of Molecular Imaging, Wuhan, Hubei 430022, P.R. China.
- Key Laboratory of Biological Targeted Therapy, The Ministry of Education, Wuhan, Hubei 430022, P.R. China.
- Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, P.R. China.
- Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, P.R. China.
ORCID-Profile: Hai Qian, Dawei Jiang, Hualong Fu
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Huang, D., Long, X., Zhong, L., Wang, Y., Di, X., Wang, Z., Zhou, S., Du, X., Zhang, Y., Qian, H., Jiang, D., & Fu, H. (2026). Peptide-Based ROR1-Targeting PET Ligands for Melanoma Tumor Imaging: Design and Preclinical Evaluation. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c00570
Vancouver
Huang D, Long X, Zhong L, Wang Y, Di X, Wang Z, et al. Peptide-Based ROR1-Targeting PET Ligands for Melanoma Tumor Imaging: Design and Preclinical Evaluation. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c00570
BibTeX
@article{Huang2026,
author = {Huang, Donglan and Long, Xingru and Zhong, Li and Wang, Yajing and Di, Xuan and Wang, Zihan and Zhou, Shuhan and Du, Xiaoyu and Zhang, Yang and Qian, Hai and Jiang, Dawei and Fu, Hualong},
title = {Peptide-Based ROR1-Targeting PET Ligands for Melanoma Tumor Imaging: Design and Preclinical Evaluation},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c00570}
}
EUVIMED